FDA Losartan Recall: Distributor Action Required for NMBA

FDA Recalls Blood Pressure Medicine Due to Carcinogenic Impurity: Distributor Action Required

The FDA issued a Class II recall for multiple lots of losartan potassium tablets on March 15, 2025, after laboratory analysis detected N-methylnitrosobutyric acid (NMBA) above acceptable limits. Wholesale drug distributors holding affected inventory must immediately quarantine stock and execute return procedures under 21 CFR 7.59, as the recall directly implicates supply chain entities in preventing further distribution of adulterated product.

Regulatory Context

This recall falls under FDA's authority to enforce adulterated drug provisions in 21 U.S.C. § 351(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. Nitrosamine impurities, including NMBA, are classified as probable human carcinogens under ICH M7(R1) guidelines. FDA has maintained heightened surveillance of angiotensin II receptor blockers (ARBs) since 2018, when widespread nitrosamine contamination first emerged in valsartan products.

Wholesale drug distributors are not passive recipients of recall notices. Under 21 CFR 207.53, distributors must maintain records enabling prompt recall execution, including lot-level inventory tracking and customer distribution records. State boards of pharmacy also impose independent recall response requirements—Ohio, for example, mandates distributor notification to customers within 48 hours of manufacturer recall notice under OAC 4729:6-3-02.

Recall Scope and Product Details

The recall affects losartan potassium tablets, 50 mg and 100 mg strengths, manufactured by Aurobindo Pharma USA and distributed under multiple private labels. FDA identified NMBA levels ranging from 0.53 to 0.89 ppm in tested lots, exceeding the acceptable intake limit of 0.096 ppm established in FDA's guidance on nitrosamine impurities.

Affected NDC numbers include:

• 59651-324-50 (50 mg, 90-count bottles)
• 59651-325-50 (100 mg, 90-count bottles)
• 16729-157-10 (50 mg, 1000-count bottles)
• 16729-158-10 (100 mg, 1000-count bottles)

Lot numbers span production dates from June 2024 through January 2025, with expiration dates extending to December 2027. The complete lot list includes 42 distinct batches distributed across 12 wholesale channels, including direct pharmacy shipments and secondary distributors.

Distributor Action Requirements

Wholesale drug distributors must execute the following within regulatory timelines:

Immediate actions (within 24 hours of receipt):

• Identify all affected lot inventory in warehouse management systems
• Quarantine stock physically and electronically to prevent further distribution
• Generate customer ship-to lists for each affected lot using DSCSA transaction history
• Initiate communication to direct customers per internal recall SOP

Documentation requirements (within 10 business days):

• Submit recall effectiveness check responses to Aurobindo Pharma indicating quantity on hand, quantity returned, and quantity distributed
• Maintain records of customer notifications, including send dates and recipient confirmation
• Document quarantine procedures and disposition of recalled product
• Preserve transaction information and transaction statements for affected lots per 21 CFR 582(d)(1)

DSCSA considerations:

Distributors who received product through multiple transaction partners must trace the chain of custody backward to verify the recalled lot originated from Aurobindo Pharma's authorized channels. Product received outside authorized trading partner networks requires enhanced verification and separate disposition documentation under state pedigree requirements still in effect during the DSCSA transition period ending November 27, 2027.

State-licensed wholesale drug distributors with active NABP accreditation face additional scrutiny during the recall effectiveness check period. NABP's accreditation criteria require demonstrable recall execution capability, and failure to document timely response can trigger compliance reviews affecting accreditation standing.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck, 1,234 hold active FDA establishment registration — a baseline requirement for handling prescription drugs subject to recall. However, the compliance score distribution reveals significant variation in verifiable compliance signals: only 28 entities (2.2%) score in the "Excellent" tier (76-100 points), while 919 entities (72%) fall in the "Fair" tier (26-50 points), indicating limited cross-verification across state licensure, accreditation, and enforcement history data sources.

The 73 entities with FDA recalls already on record represent 5.7% of the directory. Losartan recalls are not isolated incidents — nitrosamine contamination has triggered 14 separate ARB product recalls since 2018. Distributors who previously handled valsartan, irbesartan, or other recalled ARB products should document whether their recall SOPs proved adequate during those events, as FDA and state boards evaluate recall effectiveness through historical pattern analysis.

Only 63 entities in the directory hold NABP accreditation (formerly VAWD), representing 4.9% of tracked distributors. NABP-accredited entities undergo third-party compliance audits that specifically assess recall execution capability, including lot-level inventory tracking and customer notification procedures. Specialty pharmacies and hospital systems qualifying wholesale drug distributors should verify whether their trading partners maintain current NABP accreditation, as accredited status provides independent confirmation of recall response infrastructure.

Recommended Actions for Procurement and QA Teams

Cross-check your current distributor roster:

• Use the ColdChainCheck directory to verify FDA registration status for each losartan supplier in your network
• Filter by state to identify distributors subject to specific state board recall notification timelines (e.g., Ohio's 48-hour requirement)
• Review compliance scores for entities supplying cardiovascular products — scores below 26 indicate minimal verified compliance signals

Document your trading partner recall response:

• Request recall effectiveness check documentation from wholesale distributors, including quarantine records and customer notification logs
• Verify whether your distributor's DSCSA transaction history can trace affected lots backward to manufacturer origin
• Confirm whether secondary distributors in your supply chain maintain lot-level inventory controls required for targeted recall execution

Monitor for enforcement actions:

• ColdChainCheck tracks FDA warning letters and state enforcement actions against wholesale distributors who fail recall effectiveness checks
• Entities with prior recall-related citations (visible in the compliance score breakdown) pose higher operational risk during future recall events

Assess nitrosamine recall preparedness:

• ARB recalls remain ongoing — FDA continues to issue market withdrawal requests as new testing identifies contamination
• Distributors handling any ARB class medications (losartan, valsartan, irbesartan, olmesartan, candesartan, telmisartan) should maintain enhanced lot tracking and supplier qualification records

For regulatory guidance on DSCSA requirements during recall execution, see ColdChainCheck's DSCSA compliance guide. For state-specific wholesale distributor licensure and recall notification requirements, reference the state licensing overview.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult with qualified legal counsel and refer to applicable federal and state regulations when responding to FDA recalls.